Neoadjuvant chemotherapy has become the standard treatment for locally advanced rectal cancer. The focus of the research is to predict the efficacy of neoadjuvant therapy,to enrich the advantages of people and avoid the excessive treatment as well as reduce unnecessary medical expenses. In the past several years,with the rapid development of gene sequencing technology,based on the gene expression of colorectal cancer molecular subtype to predict patient’s drug sensitivity and prognosis,individual patients with different gene type undergoing precise treatment has become the focus of the current treatment.